pcDNA3.3_SOX2 Citations (8)

Originally described in: Highly Efficient Reprogramming to Pluripotency and Directed Differentiation of Human Cells with Synthetic Modified mRNA.
Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, Ebina W, Mandal PK, Smith ZD, Meissner A, Daley GQ, Brack AS, Collins JJ, Cowan C, Schlaeger TM, Rossi DJ Cell Stem Cell. 2010 Sep 29. ():. PubMed Journal

---

Articles Citing pcDNA3.3_SOX2

Articles
Anaplastic Thyroid Carcinoma: A ceRNA Analysis Pointed to a Crosstalk between SOX2, TP53, and microRNA Biogenesis. Arancio W, Carina V, Pizzolanti G, Tomasello L, Pitrone M, Baiamonte C, Amato MC, Giordano C. Int J Endocrinol. 2015;2015:439370. doi: 10.1155/2015/439370. Epub 2015 Jan 29. PubMed
Stem cell markers in glioma progression and recurrence. Hattermann K, Fluh C, Engel D, Mehdorn HM, Synowitz M, Mentlein R, Held-Feindt J. Int J Oncol. 2016 Nov;49(5):1899-1910. doi: 10.3892/ijo.2016.3682. Epub 2016 Sep 6. PubMed
High-efficiency RNA-based reprogramming of human primary fibroblasts. Kogut I, McCarthy SM, Pavlova M, Astling DP, Chen X, Jakimenko A, Jones KL, Getahun A, Cambier JC, Pasmooij AMG, Jonkman MF, Roop DR, Bilousova G. Nat Commun. 2018 Feb 21;9(1):745. doi: 10.1038/s41467-018-03190-3. PubMed
Co-activation of super-enhancer-driven CCAT1 by TP63 and SOX2 promotes squamous cancer progression. Jiang Y, Jiang YY, Xie JJ, Mayakonda A, Hazawa M, Chen L, Xiao JF, Li CQ, Huang ML, Ding LW, Sun QY, Xu L, Kanojia D, Jeitany M, Deng JW, Liao LD, Soukiasian HJ, Berman BP, Hao JJ, Xu LY, Li EM, Wang MR, Bi XG, Lin DC, Koeffler HP. Nat Commun. 2018 Sep 6;9(1):3619. doi: 10.1038/s41467-018-06081-9. PubMed
Differential expression of claudin4, occludin, SOX2 and proliferating cell nuclear antigen between basaloid squamous cell carcinoma and squamous cell carcinoma. Sato F, Bhawal UK, Tojyo I, Fujita S, Murata SI, Muragaki Y. Mol Med Rep. 2019 Aug;20(2):1977-1985. doi: 10.3892/mmr.2019.10417. Epub 2019 Jun 24. PubMed
Anti-oncogenic effects of SOX2 silencing on hepatocellular carcinoma achieved by upregulating miR-222-5p-dependent CYLD via the long noncoding RNA CCAT1. Pu J, Wu X, Wu Y, Shao Z, Luo C, Tang Q, Wang J, Wei H, Lu Y. Aging (Albany NY). 2021 Mar 22;13(8):12207-12223. doi: 10.18632/aging.103797. Epub 2021 Mar 22. PubMed
Counterintuitive production of tumor-suppressive secretomes from Oct4- and c-Myc-overexpressing tumor cells and MSCs. Li K, Sun X, Zha R, Liu S, Feng Y, Sano T, Aryal UK, Sudo A, Li BY, Yokota H. Theranostics. 2022 Mar 28;12(7):3084-3103. doi: 10.7150/thno.70549. eCollection 2022. PubMed
miR-199a-3p promotes gastric cancer progression by promoting its stemness potential via DDR2 mediation. Ren L, Ren Q, Wang J, He Y, Deng H, Wang X, Liu C. Cell Signal. 2023 Jun;106:110636. doi: 10.1016/j.cellsig.2023.110636. Epub 2023 Feb 20. PubMed

If you have published an article using this material, please email us at to have your article added to this page.